Prognostic role of BRAF mutation in stage II/III colorectal cancer receiving curative resection and adjuvant chemotherapy: A meta-analysis based on randomized clinical trials

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Zhu, Lizhen ^a   Dong, Caixia ^a   Cao, Ying ^a   Fang, Xuefeng ^a   Zhong, Chenhan ^a   Li, Dan ^a   Yuan, Ying ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; BRAF PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; META ANALYSIS; MISMATCH REPAIR; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; COLORECTAL NEOPLASMS; GENETICS; MUTATION; PROGNOSIS;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84969506706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154795     Document Type: Article

References (25)

1. Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Takahashi A, et al. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. J Surg Oncol. 2014 Dec; 110(8):982-8. doi: 10.1002/jso.23755 PMID: 25154726
2. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, et al. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 1; 21(23):5294-304. doi: 10.1158/1078-0432.CCR-15-0527 PMID: 26187617
3. Xu Q, Xu AT, Zhu MM, Tong JL, Xu XT, Ran ZH. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis. 2013 Aug; 14(8):409-16. doi: 10.1111/1751-2980.12063 PMID: 23615046
4. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer. 2013 Oct 15; 133(8):1914-25. doi: 10.1002/ijc.28153 PMID: 23494461
5. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PloS One. 2012; 7(10): e47054. doi: 10.1371/journal.pone.0047054 PMID: 23056577
6. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012 Nov 7; 104 (21):1635-46. doi: 10.1093/jnci/djs427 PMID: 23104212
7. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012 Dec 1; 18(23):6531-41. doi: 10.1158/1078-0432.CCR-12-0605 PMID: 23045248
8. Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 4; 105 (23):1789-98. doi: 10.1093/jnci/djt298 PMID: 24231454
9. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015 Dec 10; 33(35):4176-87. doi: 10.1200/JCO.2015.63.4238 PMID: 26527776
10. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep; 7(3):177-88. PMID: 3802833
12. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008; 14 (11):3408-15. doi: 10.1158/1078-0432.CCR-07-1489 PMID: 18519771
13. Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, et al. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PLoS One. 2015 May 13; 10(5):e0124612. doi: 10.1371/journal.pone.0124612 PMID: 25970543
14. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013; 45(4):346-56. doi: 10.1097/PAT.0b013e328360b61d PMID: 23594689
15. Zheng G, Tseng LH, Chen G, Haley L, Illei P, Gocke CD, et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer 2015 Oct 24; 15:779. doi: 10.1186/s12885-015-1811-y PMID: 26498038
16. Cremolini C., Di Bartolomeo M., Amatu A., Antoniotti C., Moretto R., Berenato R., et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015 Oct; 26(10):2092-7. doi: 10.1093/annonc/mdv290 PMID: 26153495
17. Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, et al. BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2014 Mar 3; 9(3):e90607. doi: 10.1371/journal.pone.0090607 PMID: 24594804
18. Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, et al. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. Br J Cancer. 2016 Jan 12; 114(1):30-6. doi: 10.1038/bjc.2015.399 PMID: 26575603
19. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol. 2014; 53(7):852-64. doi: 10.3109/0284186X.2014.895036 PMID: 24666267
20. Cui D, Cao D, Yang Y, Qiu M, Huang Y, Yi C. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep. 2014; 41(3):1291-8. doi: 10.1007/s11033-013-2974-8 PMID: 24390240
21. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. Jama. 2012; 307(13):1383-93. doi: 10.1001/jama.2012.385 PMID: 22474202
22. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012; 18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246 PMID: 22147942
23. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015 Jun 9; 112(12):1888-94. doi: 10.1038/bjc.2015.173 PMID: 25989278
24. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015; 51(5):587-94. doi: 10.1016/j.ejca.2015.01.054 PMID: 25673558
25. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Oct; 16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9 PMID: 26338525